Management Team

amotz-shemi
Amotz Shemi, PhD

CEO

Dr. Shemi is Silenseed’s co-founder and has served as the company’s Chairman of the Board of Directors and Chief Executive Officer since incorporation in 2008. Prior to founding Silenseed, from 2005 to 2008, Dr. Shemi served as the Senior Vice President Technologies at Medinol Ltd., a world leader in design, development and manufacturing of stent and stent delivery systems. Prior to that time, Dr. Shemi was the chief executive officer of several private Israeli technology companies, including Color-Chip Ltd (acquired by Sanan Optoelectronics Co. Ltd. for $300mm). Dr. Shemi holds a Ph.D. degree in Physics from the Tel Aviv University. He is a single author and co-author of many scientific papers and a single inventor and co-inventor of more than a dozen of patents.


Cheli Gonnen
Cheli Gonnen

VP Clinical Affairs

Cheli Gonnen is highly experienced in managing clinical trials in pharmaceutical and medical device companies. She brings to Silenseed her in-depth knowledge of all aspects of clinical trials at all stages. Previously Cheli served as the Clinical Trial Manager at OCON Medical Ltd., and at TCA Clinical Research. Before that Cheli served for about a decade as a Senior CRA in Merck Sharp & Dohme (MSD), covering phases I-IV in oncology and additional multiple therapeutic areas. Cheli received her M.Sc. in Biochemistry and Nutrition from the Hebrew University.
Pirak
Ettie Pirak, PhD

Director, Drug Development

Dr. Ettie Pirak, Ph.D. is a co-inventor and developer of the chimeric monoclonal antibody drug Cetuximab (Erbitux(R)); Dr Pirak serves as the Vice President of Technologies at Meytav Technological Incubator. Dr. Pirak founded Innovo Biotechnologies in 1998. She also serves as Senior Advisor at Vacciguard and Alon Therapeutics. She was also a Director of Research Collaboration at Compugen. Dr. Pirak serves as a Director of Quinova Rx Ltd., Angio B Ltd., Novotyr therapeutics and Protea. She serves as Member of Scientific Advisory Board at Allosterix Ltd. Dr. Pirak serves as a Director of Thera-P Ltd. Dr. Pirak was a Scientist at Weizmann Institute in the Chemical Immunology Department. She served as a Director of Collplant Holdings Ltd. Dr. Pirak worked for eight years as a Researcher at the Department of Chemical Immunology at the Weizmann Institute of Science. Dr. Pirak holds a Ph.D. from the Faculty of Chemistry, University of Louvain la Neuve, Belgium.
 Asher Shamir 2
Asher Shamir, CPA

VP Finance

Mr. Shamir served in Silenseed as Finance Manager since 2017 and promoted in 9/2018 to Vice President Finance, bringing with him a decade of management experience in finance. Prior to joining Silenseed, Mr. Shamir served as a finance director at Macrocure Ltd. (NASDAQ:MCUR), where he played an integral role in the company’s NASDAQ Initial Public Offering process, and leading the financial aspects of two Phase 3 clinical trials held in the US and Israel (400 patients in total). Before joining Macrocure, Mr. Shamir was a senior associate at Ernst & Young (EY) in Tel Aviv (Biotech and High-Tec segment). Mr. Shamir is a licensed Israeli CPA and holds a Bachelor degree in Accounting from the Hebrew University at Jerusalem and a Master degree at Law from Bar Ilan University.